Varian Reports Results for First Quarter of Fiscal Year 2021
News provided by
Share this article
/PRNewswire/
First Quarter 2021 Summary
Oncology Systems gross orders grew 2% in dollars or 1% in constant currency in the quarter; trailing twelve months gross orders down 5% in dollars or 6% in constant currency
13 Ethos
1 Proton order awarded in China
Total company revenues down 6% in dollars, or 8% in constant currency, to $779 million
GAAP operating earnings grew 7% at 15.1% of revenues; non-GAAP operating earnings grew 1% at 17.5% of revenues
GAAP net earnings per diluted share of $1.05; non-GAAP net earnings per diluted share of $1.14
Cash flows from operations of $141 million, up 26%
All growth rates are year-over-year. Any reference to dollars is US dollars.